As of Thursday, The Oncology Institute Inc.’s (NASDAQ:TOI) stock closed at $0.69, up from $0.67 the previous day. While The Oncology Institute Inc. has overperformed by 3.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TOI fell by -91.75%, with highs and lows ranging from $10.26 to $0.46, whereas the simple moving average fell by -79.71% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
On September 14, 2022, Guggenheim started tracking The Oncology Institute Inc. (NASDAQ: TOI) recommending Buy. A report published by Jefferies on August 15, 2022, Initiated its previous ‘Buy’ rating for TOI.
Analysis of The Oncology Institute Inc. (TOI)
Further, the quarter-over-quarter increase in sales is 36.50%, showing a positive trend in the upcoming months.
One of the most important indicators of The Oncology Institute Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 0.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and TOI is recording 165.73K average volume. On a monthly basis, the volatility of the stock is set at 18.92%, whereas on a weekly basis, it is put at 14.81%, with a loss of -0.95% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.50, showing growth from the present price of $0.69, which can serve as yet another indication of whether TOI is worth investing in or should be passed over.
How Do You Analyze The Oncology Institute Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 74.90% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in TOI shares?
The recent increase in stakes in TOI appears to be a result of several institutional investors and hedge funds increasing their positions. Fidelity Management & Research Co’s position in TOI has increased by 0.01% in the first quarter. The company now owns 12,001,982 shares of the stock, with a value of $16.92 million, following the purchase of 1,713 additional shares during the last quarter. During the last quarter, the company picked up 0 additional shares for a total stake of worth $4.74 million, bringing number of shares owned by the company to 3,360,052.
At the end of the first quarter, BlackRock Fund Advisors increased its TOI holdings by 116.30% and now holds 1.47 million TOI shares valued at $2.07 million with the added 0.79 million shares during the period. TOI shares are owned by institutional investors to the tune of 74.90% at present.
